Total Payments
$202,618
2024 Payments
$39,920
Companies
8
Transactions
34
Payment Breakdown by Category
Royalty/License$181,256 (89.5%)
Consulting$15,692 (7.7%)
Research$4,000 (2.0%)
Food & Beverage$895.39 (0.4%)
Travel$774.63 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $181,256 | 16 | 89.5% |
| Consulting Fee | $15,692 | 3 | 7.7% |
| Unspecified | $4,000 | 1 | 2.0% |
| Food and Beverage | $895.39 | 11 | 0.4% |
| Travel and Lodging | $774.63 | 3 | 0.4% |
Payments by Type
General
$198,618
33 transactions
Research
$4,000
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Quidel Corporation | $157,571 | 13 | $0 (2023) |
| Ortho-Clinical Diagnostics, Inc. | $30,126 | 4 | $0 (2024) |
| Kyowa Kirin, Inc. | $9,905 | 10 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,000 | 1 | $0 (2021) |
| PFIZER INC. | $500.00 | 1 | $0 (2017) |
| Chugai Pharmaceutical Co., Ltd. | $403.82 | 3 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $75.87 | 1 | $0 (2020) |
| AKEBIA THERAPEUTICS INC | $35.42 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,920 | 13 | Ortho-Clinical Diagnostics, Inc. ($30,126) |
| 2023 | $24,930 | 3 | Quidel Corporation ($24,819) |
| 2022 | $6,442 | 1 | Quidel Corporation ($6,442) |
| 2021 | $29,535 | 3 | Quidel Corporation ($25,535) |
| 2020 | $22,049 | 3 | Quidel Corporation ($21,973) |
| 2019 | $25,605 | 4 | Quidel Corporation ($25,411) |
| 2018 | $25,744 | 3 | Quidel Corporation ($25,622) |
| 2017 | $28,393 | 4 | Quidel Corporation ($27,770) |
All Payment Transactions
34 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/21/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Consulting Fee | Cash or cash equivalent | $8,750.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/21/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | Cash or cash equivalent | $82.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/10/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/10/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/10/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/10/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/09/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $465.77 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/09/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $226.86 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/09/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $119.11 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/01/2024 | Ortho-Clinical Diagnostics, Inc. | — | Royalty or License | Cash or cash equivalent | $2,819.42 | General |
| 07/25/2024 | Ortho-Clinical Diagnostics, Inc. | — | Royalty or License | Cash or cash equivalent | $8,568.11 | General |
| 02/14/2024 | Ortho-Clinical Diagnostics, Inc. | — | Royalty or License | Cash or cash equivalent | $10,170.79 | General |
| 01/25/2024 | Ortho-Clinical Diagnostics, Inc. | — | Royalty or License | Cash or cash equivalent | $8,568.11 | General |
| 10/14/2023 | Kyowa Kirin, Inc. | — | Food and Beverage | In-kind items and services | $111.17 | General |
| 07/26/2023 | Quidel Corporation | — | Royalty or License | Cash or cash equivalent | $6,261.10 | General |
| 01/25/2023 | Quidel Corporation | — | Royalty or License | Cash or cash equivalent | $18,558.12 | General |
| 07/13/2022 | Quidel Corporation | MicroVue Bone (Device) | Consulting Fee | Cash or cash equivalent | $6,441.88 | General |
| Category: Bone Health | ||||||
| 07/14/2021 | Quidel Corporation | MicroVue Bone (Device) | Royalty or License | Cash or cash equivalent | $10,131.15 | General |
| Category: Bone Health | ||||||
| 04/04/2021 | Takeda Pharmaceuticals U.S.A., Inc. | NATPARA (PARATHYROID HORMONE) (Drug) | — | Cash or cash equivalent | $4,000.00 | Research |
| Study: 601090: Natpara Next Generation Usability Evaluation • Category: INTERNAL MEDICINE | ||||||
| 01/20/2021 | Quidel Corporation | MicroVue Bone (Device) | Royalty or License | Cash or cash equivalent | $15,403.95 | General |
| Category: Bone Health | ||||||
| 10/16/2020 | Bayer HealthCare Pharmaceuticals Inc. | Non-Covered | Food and Beverage | In-kind items and services | $75.87 | General |
| 07/20/2020 | Quidel Corporation | QuickVue (Device) | Royalty or License | Cash or cash equivalent | $9,596.05 | General |
| Category: SARS | ||||||
| 01/20/2020 | Quidel Corporation | MicroVue (Device) | Royalty or License | Cash or cash equivalent | $12,376.60 | General |
| Category: Bone Health | ||||||
| 09/27/2019 | Chugai Pharmaceutical Co., Ltd. | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $158.73 | General |
| Category: None | ||||||
| 07/16/2019 | Quidel Corporation | FGF-23 (Device) | Royalty or License | Cash or cash equivalent | $12,842.94 | General |
| Category: Bone Health | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 601090: Natpara Next Generation Usability Evaluation | Takeda Pharmaceuticals U.S.A., Inc. | $4,000 | 1 |
About Dr. Harald Jueppner, MD
Dr. Harald Jueppner, MD is a Pediatrics healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043261225.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Harald Jueppner, MD has received a total of $202,618 in payments from pharmaceutical and medical device companies, with $39,920 received in 2024. These payments were reported across 34 transactions from 8 companies. The most common payment nature is "Royalty or License" ($181,256).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Endocrinology
- Location Boston, MA
- Active Since 05/13/2006
- Last Updated 09/11/2025
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1043261225
Products in Payments
- FGF-23 (Device) $78,802
- MicroVue Bone (Device) $31,977
- MicroVue (Device) $12,377
- Crysvita (Drug) $9,794
- QuickVue (Device) $9,596
- NATPARA (PARATHYROID HORMONE) (Drug) $4,000
- Non-Covered Product (Drug) $403.82
- Non-Covered $75.87
- AURYXIA (Drug) $35.42
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Boston
Dr. R Ezekowitz, Mbch Dphl, MBCH DPHL
Pediatrics — Payments: $1.2M
Pediatrics $1.2M
Stephen Pelton, Md, MD
Pediatrics — Payments: $456,322
Pediatrics $456,322
Tanya Laidlaw, M.d, M.D
Pediatrics — Payments: $307,922
Pediatrics $307,922
Rachael Grace, Md, MD
Pediatrics — Payments: $175,958
Pediatrics $175,958
Dr. Thomas Kinane, Md, MD
Pediatrics — Payments: $175,709
Pediatrics $175,709
Courtney Hanna
Pediatrics — Payments: $149,231
Pediatrics $149,231